Current Status and Future Therapeutic Perspectives of Glioblastoma Multiforme (GBM) Therapy: A Review

Overview

Journal Biomed Pharmacother

Specialties Biology
General Medicine
Pharmacology

Date 2017 Jun 6

PMID 28582760

Citations 118

Authors

Komal Anjum

Bibi Ibtesam Shagufta

Syed Qamar Abbas

Seema Patel

Ishrat Khan

Sayed Asmat Ali Shah

Najeeb Akhter

Syed Shams Ul Hassan

Affiliations

Soon will be listed here.

Abstract

Glioblastoma multiforme (GBM) is the deadliest form of heterogeneous brain cancer. It affects an enormous number of patients every year and the survival is approximately 8 to 15 months. GBM has driven by complex signaling pathways and considered as a most challenging to treat. Standard treatment of GBM includes surgery, radiation therapy, chemotherapy and also the combined treatment. This review article described inter and intra- tumor heterogeneity of GMB. In addition, recent chemotherapeutic agents, with their mechanism of action have been defined. FDA-approved drugs also been focused over here and most importantly highlighting some natural and synthetic and novel anti- glioma agents, that are the main focus of researchers nowadays.

Citing Articles

The Small Molecules of Plant Origin with Anti-Glioma Activity.

Liu X, Su Y, Yang Y, Li R, Zhang Z Int J Mol Sci. 2025; 26(5).

PMID: 40076568 PMC: 11900624. DOI: 10.3390/ijms26051942.

Glioblastoma multiforme: insights into pathogenesis, key signaling pathways, and therapeutic strategies.

Pouyan A, Ghorbanlo M, Eslami M, Jahanshahi M, Ziaei E, Salami A Mol Cancer. 2025; 24(1):58.

PMID: 40011944 PMC: 11863469. DOI: 10.1186/s12943-025-02267-0.

Mathematical modeling of multicellular tumor spheroids quantifies inter-patient and intra-tumor heterogeneity.

Malik A, Nguyen K, Nardini J, Krona C, Flores K, Nelander S NPJ Syst Biol Appl. 2025; 11(1):20.

PMID: 39955270 PMC: 11830081. DOI: 10.1038/s41540-025-00492-3.

Isolation and Characterization of the First Antigen-Specific EGFRvIII vNAR from Freshwater Stingray ( spp.) as a Drug Carrier in Glioblastoma Cancer Cells.

Manzanares-Guzman A, Alfonseca-Ladron de Guevara A, Reza-Escobar E, Burciaga-Flores M, Canales-Aguirre A, Esquivel-Solis H Int J Mol Sci. 2025; 26(3).

PMID: 39940647 PMC: 11817625. DOI: 10.3390/ijms26030876.

Deciphering the dose-dependent effects of thymoquinone on cellular proliferation and transcriptomic changes in A172 glioblastoma cells.

Pandey R, Natarajan P, Reddy U, Du W, Sirbu C, Sissoko M PLoS One. 2025; 20(1):e0318185.

PMID: 39874307 PMC: 11774404. DOI: 10.1371/journal.pone.0318185.